TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company, is dedicated to developing T cell receptor (TCR)-engineered T cell therapies (TCR-T) aimed at treating cancer. On February 25, 2026, the company announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 4, 2026. The event will take place at the Boston Marriott Copley Place, with TScan's presentation set for 11:50 a.m. Eastern Time. The presentation will be hybrid, allowing for both in-person and virtual attendance, followed by a Q&A session led by analysts. Interested parties can access a live webcast through the "Events and Presentations" section of TScan's website, with a replay available for 90 days post-event.

TScan Therapeutics is at the forefront of TCR-T therapy development, with its lead candidate currently in the ALLOHA™ Phase 1 trial, aimed at patients with hematologic malignancies to reduce relapse risk following allogeneic hematopoietic cell transplantation. In addition to its hematologic focus, TScan is actively exploring multiple candidates for solid tumors and developing innovative in vivo engineering methods. Through its target discovery platform, the company is also investigating novel targets relevant to T cell-mediated autoimmune disorders, expanding its potential therapeutic applications beyond oncology.

This forthcoming conference is an opportunity for TScan to showcase its advances in TCR-T therapies and engage with investors and analysts, potentially driving interest in its ongoing projects and strategic direction within the competitive biotech landscape.

TScan Therapeutics, Inc. (Nasdaq: TCRX) is an intriguing player in the biotech sector, focusing on T cell receptor (TCR)-engineered T cell therapies for cancer. As the company prepares for its participation in the TD Cowen 46th Annual Health Care Conference, investors should closely monitor its developments.

Given TScan's focus on TCR-T therapies, particularly its lead candidate targeting hematologic malignancies post-transplantation, there are several factors at play that could influence market performance. The ALLOHA™ Phase 1 trial represents a significant milestone, as successful outcomes could bolster clinical credibility and attract further investment. This is especially crucial given the competitive landscape of cancer therapeutics, where innovations can quickly shift investor sentiment.

Investors should pay particular attention to the company's advancements in solid tumor therapies and in vivo engineering methods. Expansion into solid tumors could diversify TScan’s pipeline and mitigate risk associated with reliance on a single indication. Moreover, the application of their target discovery platform to autoimmune disorders showcases the technological versatility of TScan’s offerings, which could open new revenue channels.

Additionally, the company's participation in the TD Cowen Conference will provide insights into management's strategy, as well as updates on clinical trials and product development timelines. Engaging with analysts during the Q&A session may also unveil pivotal data and company outlook, presenting an opportune moment for investors to gauge market sentiment.

In summary, while TScan Therapeutics presents promising prospects, potential investors should consider both the inherent risks of clinical-stage biotech investments and the opportunities arising from their innovative TCR-T therapies. Keeping an eye on the outcomes of their conference participation and further clinical developments will be pivotal in making informed investment decisions.